Tolerability of the epoetin-beta multidose formulation (Reco-Pen®) in patients with renal anaemia

Clinical Drug Investigation

Volumn 20, Issue 3, 2000, Pages 151-158

  Ruiz, P ^a   Balcke, P ^b   Martinez, J M ^c   Harris, K ^d  

^a HOSPITAL SEVERO OCHOA   (Spain)

^b Krankenhaus St Polten   (Austria)

^c HOSPITAL DE GALDAKAO   (Spain)

^d LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; BLOOD PRESSURE; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; HEART INFARCTION; HEMATEMESIS; HEMATOCRIT; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERITONITIS; PNEUMONIA; PRIORITY JOURNAL; SELF INJECTION; SEPSIS; THROMBOSIS;

EID: 0033790981     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200020030-00002     Document Type: Article

References (27)

1. Epoetin beta. A review of its pharmacological properties and Clinical use in the management of anaemia associated with chronic renal failure
2. The safety of treatment with recombinant human erythropoietin in clinical use: A review of controlled studies
3. Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic uraemic patients
4. Regression of left ventricular hypertrophy after partial correction of anaemia with erythropoietin in patients on hemodialysis: A prospective study
5. Follow-up of cardiac changes induced by anemia compensation in normotensive hemodialysis patients with left-ventricular hypertrophy
6. The prognostic importance of left ventricular geometry in uremic cardiopathy
7. Trends in anemia treatment with erythropoietin usage and patient outcomes
8. The impact of haemocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity - The experience of the Lombardy Dialysis Registry
9. Effect of EPO therapy on mortality in hemodialysis. Preliminary results from an EDTA-Registry Study
10. National Kidney Foundation Clinical practice guidelines for the treatment of anaemia of chronic renal failure Dialysis outcomes quality initiative
11. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. European best practice guidelines for the management of anaemia in patients with chronic renal failure
12. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties
13. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta
14. Assessment of pain after subcutaneous injections of erythropoietin in patients receiving haemodialysis
15. Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: A randomised double-blind, crossover study
16. Pain after subcutaneous injection of erythropoietin
17. Pain at the injection site of subcutaneously administered erythropoietin (EPO) in maintenance hemodialysis patients: A comparison of two brands of EPO
18. Pain at the injection site of subcutaneously-administered erythropoietin: Phosphate-buffered epoetin alpha compared to citrate-buffered epoetin alpha and epoetin beta
19. The subcutaneous administration route of epoetin: Advantages, pain at injection site and patient acceptance
20. Analysis of the efficacy of measures to reduce pain after subcutaneous administration of epoetin alfa
21. A comparison of the discomfort of subcutaneous injections of epoetin beta and phosphate-buffered epoetin alpha
22. Tolerability and efficacy of multidose formulations of epoetin beta
23. The use of epoetin beta in anemic predialysis patients with chronic renal failure
24. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial
25. Use of recombinant human erythropoietin (rh-EPO) in the treatment of anemia in hemodialysis patients: A multicenter Italian experience
26. Cost benefits of low dose subcutaneous erythropoietin in patients With anaemia of end stage renal disease
27. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis